USPTO granted patent US12606571B2 to Turning Point Therapeutics, Inc. for macrocyclic compounds that inhibit SRC and MET and/or CSF1R, pharmaceutical compositions thereof, and methods of using such compounds to treat cancer. The patent contains 9 claims and was granted on April 21, 2026.
USPTO granted patent US12608442B2 to inventor Jiazuo Zhang for a method of selecting machine learning models in wellbore operations using feature merging across multiple time windows. The patent covers receiving sensor data from subsurface formations in wellbores, merging with previously cached historical datasets that spatially overlap, and selecting appropriate ML models based on merged datasets.
